Literature DB >> 21502562

Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and biochemical presentation.

Marlene Aglony1, Alejandro Martínez-Aguayo, Cristian A Carvajal, Carmen Campino, Hernán García, Rodrigo Bancalari, Lillian Bolte, Carolina Avalos, Carolina Loureiro, Pamela Trejo, Karin Brinkmann, Vinka Giadrosich, Verónica Mericq, Ana Rocha, Alejandra Avila, Viviana Perez, Andrea Inostroza, Carlos E Fardella.   

Abstract

Familial hyperaldosteronism type 1 is an autosomal dominant disorder attributed to a chimeric CYP11B1/CYP11B2 gene (CG). Its prevalence and manifestation in the pediatric population has not been established. We aimed to investigate the prevalence of familial hyperaldosteronism type 1 in Chilean hypertensive children and to describe their clinical and biochemical characteristics. We studied 130 untreated hypertensive children (4 to 16 years old). Blood samples for measuring plasma potassium, serum aldosterone, plasma renin activity, aldosterone/renin ratio, and DNA were collected. The detection of CG was performed using long-extension PCR. We found 4 (3.08%) of 130 children with CG who belonged to 4 unrelated families. The 4 patients with CG had very high aldosterone/renin ratio (49 to 242). In addition, we found 4 children and 5 adults who were affected among 21 first-degree relatives. Of the 8 affected children, 6 presented severe hypertension, 1 presented prehypertension, and 1 presented normotension. High serum aldosterone levels (>17.7 ng/dL) were detected in 6 of 8 subjects (range: 18.6 to 48.4 ng/dL) and suppressed plasma renin activity (≤0.5 ng/mL per hour) and high aldosterone/renin ratio (>10) in 8 of 8 children (range: 49 to 242). Hypokalemia was observed in only 1 of 8 children. We demonstrated that the prevalence of familial hyperaldosteronism type 1 in a pediatric hypertensive pediatric population was surprisingly high. We found a high variability in the clinical and biochemical characteristics of the affected patients, which suggests that familial hyperaldosteronism type 1 is a heterogeneous disease with a wide spectrum of presentations even within the same family group.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502562     DOI: 10.1161/HYPERTENSIONAHA.110.168740

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

Review 1.  Management of blood pressure in children.

Authors:  Rossana Malatesta-Muncher; Mark M Mitsnefes
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-05       Impact factor: 2.894

2.  Monogenic forms of low-renin hypertension: clinical and molecular insights.

Authors:  Priyanka Khandelwal; Jaap Deinum
Journal:  Pediatr Nephrol       Date:  2021-08-20       Impact factor: 3.651

Review 3.  Role of KCNJ5 in familial and sporadic primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; William E Rainey; Franco Veglio; Tracy Ann Williams
Journal:  Nat Rev Endocrinol       Date:  2012-12-11       Impact factor: 43.330

4.  GRAde: a long-read sequencing approach to efficiently identifying the CYP11B1/CYP11B2 chimeric form in patients with glucocorticoid-remediable aldosteronism.

Authors:  Yu-Ching Wu; Chia-I Chen; Peng-Ying Chen; Chun-Hung Kuo; Yi-Hsuan Hung; Kang-Yung Peng; Vin-Cent Wu; Jyy-Jih Tsai-Wu; Chia-Lang Hsu
Journal:  BMC Bioinformatics       Date:  2022-01-10       Impact factor: 3.169

5.  Characteristics and Outcomes in Primary Aldosteronism Patients Harboring Glucocorticoid-Remediable Aldosteronism.

Authors:  Chung-Yi Cheng; Hung-Wei Liao; Kang-Yung Peng; Tso-Hsiao Chen; Yen-Hung Lin; Jeff S Chueh; Vin-Cent Wu
Journal:  Biomedicines       Date:  2021-12-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.